Somewhat Positive Media Coverage Somewhat Unlikely to Affect Atara Biotherapeutics (ATRA) Stock Price
News stories about Atara Biotherapeutics (NASDAQ:ATRA) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Atara Biotherapeutics earned a daily sentiment score of 0.07 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 46.7976655427441 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the news headlines that may have effected Accern Sentiment Analysis’s rankings:
- Atara Biotherapeutics Announces FDA Clearance to Proceed with Enrollment at U.S. Sites for Ongoing Global Phase 1 Clinical Study to Evaluate ATA188 in Patients with Progressive or Relapsing-Remitting Multiple Sclerosis (finance.yahoo.com)
- Investors Buy High Volume of Put Options on Atara Biotherapeutics (ATRA) (americanbankingnews.com)
- Atara Biotherapeutics Sees Unusually Large Options Volume (ATRA) (americanbankingnews.com)
- Atara Biotherapeutics, Inc. (ATRA) – Watch List Unusual Volume stock – Wall Street Morning (wallstreetmorning.com)
- Heading Towards a Potential Reversal? Abercrombie & Fitch Co. (ANF), Atara Biotherapeutics, Inc. (ATRA) – Market Movers (financialqz.com)
Atara Biotherapeutics (NASDAQ:ATRA) opened at $22.15 on Friday. Atara Biotherapeutics has a 12 month low of $11.80 and a 12 month high of $23.00. The stock has a market capitalization of $670.36, a PE ratio of -6.38 and a beta of 1.27.
Several equities analysts have recently commented on the company. BidaskClub raised Atara Biotherapeutics from a “hold” rating to a “buy” rating in a research note on Thursday. Canaccord Genuity reaffirmed a “buy” rating on shares of Atara Biotherapeutics in a research note on Friday, December 29th. Jefferies Group reaffirmed a “buy” rating and issued a $30.00 price target on shares of Atara Biotherapeutics in a research note on Thursday, October 5th. ValuEngine raised Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Friday, December 29th. Finally, Citigroup raised Atara Biotherapeutics from a “sell” rating to a “neutral” rating and set a $18.00 price target on the stock in a research note on Wednesday, January 3rd. Four analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $26.00.
In other news, EVP Christopher Haqq sold 6,000 shares of the stock in a transaction dated Monday, October 16th. The stock was sold at an average price of $14.35, for a total value of $86,100.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO John Mcgrath sold 32,000 shares of the stock in a transaction dated Friday, December 29th. The shares were sold at an average price of $20.00, for a total value of $640,000.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 121,788 shares of company stock worth $2,194,934. 16.20% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect Atara Biotherapeutics (ATRA) Stock Price” was first posted by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece of content can be accessed at https://www.watchlistnews.com/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-atara-biotherapeutics-atra-stock-price/1804300.html.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.